Mounjaro EPAR Public Assessment Report
By binding to GLP-1 receptors, semaglutide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways
Further, while GLP-1RAs have a positive impact on the LVEF, it seems to be inconsistent in most patients with heart failure and effects are quite limited [174]
You can stop taking it without experiencing rebound hunger, metabolic compensation, or the rapid weight regain that characterizes some pharmacological interventions
So, I very much use that as momentum. On Insulin Resistance One of the main draws of Parkers account is her vulnerability, showing both her highs and lows as they come